Morgan Stanley has lowered its price target on Recursion Pharmaceuticals (NASDAQ:RXRX) to $5 from $8, while maintaining an ...

“Small experiments with radical intent. That’s how we live our lives at Punchcard ,” says Jenkins, CEO of the Edmonton-based digital transformation studio, referencing advice he once received from an ...

REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsREC-4539, a ...

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an unspecified up-front payment, research costs ...

Recursion is eliminating approximately 20% of its workforce, in a restructuring that reflects challenges seen across the biopharma industry.

All told, Recursion is “deprioritizing” three clinical-stage programs, pausing another and winding down a single preclinical program in an undisclosed target, the company revealed in its first ...

Recursion will host a (L)earnings Call on May 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm BST from Recursion’s X (formerly Twitter), LinkedIn, and YouTube accounts giving analysts, investors ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning ...

Recursion Pharmaceuticals' stock is soaring today on news the FDA is planning on phasing out some animal testing, replacing it with AI. Read my RXRX stock thesis.

Cathie Wood in a latest program on CNBC talked about Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) and explained why she’s bullish on the stock because of AI catalysts: ...

The fund will provide up to $250,000 in capital, 12 months of lab space and access to Altitude Lab’s accelerator program for biotech startups that have been reviewed for Small Business ...

Funding awards also come with admission to the Altitude accelerator program, ... Recursion Pharmaceuticals formed in 2013, ... Gibson said NIH small business innovation research (SBIR) ...